SCM
TAK icon

Soleus Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Soleus Capital Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,180,000
Closed -$15.6M – 92
2024
Q4 		$15.6M Buy
1,180,000
+680,000
+136% +$9.34M 0.98% 30
2024
Q3 		$7.11M Buy
+500,000
New +$7.09M 0.55% 48

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Soleus Capital Management's TAK Position: Q1 2025 in Review

Soleus Capital Management sold out of Takeda Pharmaceutical (TAK) in Q1 2025, closing a stake of 1,180,000 shares — an estimated $15.6M sold.

Soleus Capital Management first reported a position in TAK in Q3 2024 and held it in 2 quarters. The position peaked at $15.6M in Q4 2024. 307 funds tracked by Wall St. Rank hold TAK as of Q1 2025.

  • Soleus Capital Management reported no remaining Takeda Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Soleus Capital Management sold 1,180,000 Takeda Pharmaceutical shares in Q1 2025, an estimated $15.6M.
  • Soleus Capital Management first reported a position in Takeda Pharmaceutical in Q3 2024 and held it in 2 quarters.
  • Soleus Capital Management's Takeda Pharmaceutical position peaked at $15.6M in Q4 2024.
  • 307 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2025.

Based on Soleus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.